



Charles Lister, Esq
Head of Blood Policy
Health Services Directorate
Wellington House
135-155 Wellington Road
London, SE1 8UG

30th April 2001

Dear Mr Lister,

Further to my recent telephone conversation with you, please find attached a copy of Novo Nordisk's current position document in respect of recombinant factor VIIa. I hope that you will find this useful in informing policy development in the area of haemophiliacs with inhibitors.

I am grateful to you for agreeing in principle to meet me and one or two colleagues from Novo Nordisk to discuss this area of health policy. I think we agreed that we would leave such a meeting until after the General Election (if that proves to be in June) but to meet more quickly if the Election is postponed.

As we discussed, I will contact you again in early June. In the meantime, I would be interested in any initial comments you might have on the attached document.

Yours sincerely,

Berkeley Green
Government Relations

GRO-C - Berkeley Greenwood